Search Results

You are looking at 1 - 10 of 637 items for :

  • "immunotherapy" x
  • Refine by Access: All x
Clear All
Full access

Role of Immunotherapy for Renal Cell Cancer in 2011

Saby George, Roberto Pili, Michael A. Carducci, and Jenny J. Kim

understanding of immune regulation has led to the advancement of targeted immunotherapy using immune checkpoint inhibitors that have shown promising activity and are moving forward in clinical development. This article focuses on the current status of

Full access

Similar Efficacy Observed for First-Line Immunotherapy in Racial/Ethnic Minority Patients With Metastatic NSCLC

Matthew Lee, Jianyou Liu, Emily Miao, Shuai Wang, Frank Zhang, John Wei, Julie Chung, Xiaonan Xue, Balazs Halmos, H. Dean Hosgood, and Haiying Cheng

targeted therapies, and the paradigm-shifting incorporation of immunotherapy. Because more than half of patients with advanced non–small cell lung cancer (NSCLC) do not harbor a targetable alteration, they are treated instead with standard first

Full access

Role of Immunotherapy in Triple-Negative Breast Cancer

Tanya E. Keenan and Sara M. Tolaney

predominant systemic therapy for most metastatic TNBC (mTNBC) is chemotherapy, but responses are often short-lived, and patients have a median overall survival (OS) of 12 to 18 months. 1 Therefore, improved therapies are urgently needed. Immunotherapy has

Full access

Impact of Immunotherapy on the Survival of Patients With Cancer and Brain Metastases

Saber Amin, Michael Baine, Jane Meza, and Chi Lin

median survival in patients with BMs from renal cell carcinoma by more than 9 months (16.6 vs 7.2 months). 21 The development of immunotherapeutics offers an exciting opportunity for the treatment of BMs. 12 Immunotherapy has shown great success in the

Full access

BRAF/MEK Inhibition as a Bridge to Immunotherapy for Symptomatic BRAF V600 Melanoma Brain Metastases: A Case Series

Jacob Strelnikov, Alice Zhou, Omar Butt, Michael Ansstas, and George Ansstas

brain MRI after radiotherapy and 6 weeks of BRAF and MEK inhibitor therapy. (C) Restaging scans after 6 weeks of immunotherapy. (D) Restaging brain MRI 30 months from treatment start. Selected images maximize viewable lesion burden. Table 1

Full access

Prognostic and Predictive Markers for Patients With Anal Cancer

Emma B. Holliday, Arjun Peddireddy, and Van K. Morris

Immunotherapy Benefit In recent years, immunotherapy with anti–PD-(L)1 antibodies has demonstrated modest clinical benefit for some patients with unresectable or metastatic SCCA ( Table 2 ). Single-arm prospective trials for patients with incurable SCCA have

Full access

Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma

Pooja Ghatalia and Elizabeth R. Plimack

metastatic UC. Additionally, early data from clinical trials combining chemotherapy with immunotherapy in the frontline setting are also now available. This article reviews the data that led to FDA approval of these agents for mUC in patients who are

Full access

Anaplastic Classic Kaposi Sarcoma: PD-L1 Expression and Response to Immunotherapy: A Case Report and Review of the Literature

Ivan Lolli, Anna Maria Valentini, Angela Dalia Ricci, and Raffaele Armentano

-refractory disease, and the absence of approved therapeutic options except for recourse to highly mutilating surgery, refused by the patient, rescue treatment with immunotherapy was proposed. After obtaining the patient’s informed consent, on December 31, 2020, off

Full access

Immune-Related Adverse Events Among COVID-19–Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade

Adam J. Widman, Bevin Cohen, Vivian Park, Tara McClure, Jedd Wolchok, and Mini Kamboj

type(s) of ICI administration, and death during the follow-up period. We determined the incidence of irAEs in patients who received immunotherapy within 90 days before or after the first dose of an mRNA SARS-CoV-2 vaccine, following up patients for 90

Full access

Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair–Deficient Colorectal Cancer

Bin-Yi Xiao, Xuan Zhang, Tai-Yuan Cao, Dan-Dan Li, Wu Jiang, Ling-Heng Kong, Jing-Hua Tang, Kai Han, Chen-Zhi Zhang, Wei-Jian Mei, Jian Xiao, Zhi-Zhong Pan, Yun-Feng Li, Xiao-Shi Zhang, and Pei-Rong Ding

achievable, but prolonged immunotherapy was usually prescribed when there was continuing tumor shrinkage on radiology. For patients whose tumor had achieved clinical CR (cCR; defined as the absence of tumor on radiologic and endoscopic findings), a watch